Determination of genotypes using a fully automated molecular detection system

Area of Science:

• Genetics and Genomics
• Molecular Diagnostics
• Personalized Medicine

Background:

• Pharmacogenomics adoption is hindered by complex, costly testing and reimbursement issues.
• Physician training and payer reluctance also impede the integration of pharmacogenomics into clinical practice.
• Despite challenges, the value of pharmacogenomics in improving patient outcomes is increasingly recognized.

Purpose of the Study:

• To evaluate a fully automated molecular detection system for human genotyping.
• To assess the system's capability for automated sample preparation, assay, and analysis.
• To determine if the system provides actionable results for clinical application.

Main Methods:

• 254 individuals' genotypes were determined using bidirectional DNA sequencing.
• This data was used to train the automated system's imaging software.
• The software was trained to distinguish three genotypes at CYP2C9*2, CYP2C9*3, and VKORC1 loci.

Main Results:

• The automated system's software correctly identified genotypes in 100% of evaluated individuals.
• No further user analysis was required after the automated process.
• The system achieved results identical to traditional DNA sequencing methods.

Conclusions:

• The EncompassMDx workstation offers automated, unattended genotyping from whole blood.
• It requires less technical expertise than conventional DNA sequencing.
• This system has the potential to significantly reduce pharmacogenomics testing costs and complexity, promoting wider use.